Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cluster analysis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    41 result(s) found for: Cluster analysis. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2007-004252-37 Sponsor Protocol Number: IPH1101-204 Start Date*: 2007-10-11
    Sponsor Name:Innate Pharma
    Full Title: A Phase I/II open label study to assess efficacy and safety of IPH1101 associated with low dose of interleukin 2, as add-on therapy to imatinib in CML patients with residual molecular disease
    Medical condition: Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003502-16 Sponsor Protocol Number: DasaHIT Start Date*: 2016-08-11
    Sponsor Name:Friedrich-Schiller-Universität Jena
    Full Title: Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors...
    Medical condition: Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004109-25 Sponsor Protocol Number: P261-402 Start Date*: 2012-05-03
    Sponsor Name:Upsher-Smith Laboratories, Inc.
    Full Title: An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects with Seizure Clusters
    Medical condition: Epilepsy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10015052 Epileptic seizure LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004321-25 Sponsor Protocol Number: NordDutchCML009 Start Date*: 2013-04-03
    Sponsor Name:VU University Medical Center
    Full Title: A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon α2b in patients with suboptimal molecular response or stable detectable molecular residual disease af...
    Medical condition: Chronic myeloid leukemia in chronic phase and ≥ 2 years on Imatinib treatment with suboptimal molecular response (BCR-ABL level above 0.01% IS).
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) SE (Completed) NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000968-34 Sponsor Protocol Number: CAMN107ADE20 Start Date*: 2015-10-07
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A Phase IV single arm, multicenter, open-label study assessing deep molecular response in adult patients with newly diagnosed Philadelphia chromosome positive CML in chronic phase after two years o...
    Medical condition: The trial aims to evaluate the efficacy and quality of life of nilotinib 300mg BID in patients with chronic myleoid leukemia in chronic phase.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003069-39 Sponsor Protocol Number: VARIANT Start Date*: 2023-06-01
    Sponsor Name:Friedrich-Schiller-Universität Jena
    Full Title: Venetoclax after TKI to target persisting stem cells in CML
    Medical condition: Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-024262-22 Sponsor Protocol Number: CML-V Start Date*: 2012-08-24
    Sponsor Name:Friedrich-Schiller-Universität Jena
    Full Title: Treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase with nilotinib vs. nilotinib plus interferon alpha induction and nilotini...
    Medical condition: chronic phase CML
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018419-14 Sponsor Protocol Number: CAMN107A2120 Start Date*: 2010-10-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, open-label, pharmacokinetic study of oral nilotinib in pediatric patients with Gleevec® (imatinib)-resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with ...
    Medical condition: pediatric patients with Gleevec® (imatinib)- resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with refractory/relapsed Ph+ ALL
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009700 CML LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000077-68 Sponsor Protocol Number: CAMN107ADE18T Start Date*: 2013-12-10
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: Imatinib continuation versus Nilotinib 300 mg twice daily in patients with chronic myeloid leukemia (CML) in chronic phase and major molecular response (MMR) without molecular response ≥ 4.5 log (M...
    Medical condition: chronic myeloid leukemia (CML) in 1st chronic phase and confirmed major molecular response (MMR)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10009700 CML LLT
    19.0 100000004864 10066506 CML progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001206-24 Sponsor Protocol Number: 16901 Start Date*: 2007-07-31
    Sponsor Name:UMCG
    Full Title: Effect of selective COX-2 inhibition on neuroinflammation in Parkinson's disease
    Medical condition: Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004461-85 Sponsor Protocol Number: CCOA556B2401 Start Date*: 2016-04-06
    Sponsor Name:Novartis Pharma AG
    Full Title: A cluster randomized, single-centre, controlled, parallel,12-month prospective study and additional 12-month follow-up in Africa of malaria incidence in a community setting following systematic tre...
    Medical condition: This study assessed the impact of the systematic detection by Rapid Diagnostic Test (RDT) and treatment of asymptomatic carriers of malaria parasites (P. falciparum) with COA566 on the number of cl...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10025487 Malaria PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-000459-10 Sponsor Protocol Number: PADIT Start Date*: 2014-06-10
    Sponsor Name:Population Health Research Institute (PHRI)
    Full Title: A cluster Crossover Trial Comparing Conventionl vs Incremental Antibiotic Therapy for the Prevention or Arrhytmia Device Infection
    Medical condition: high-risk patients undergoing arrhythmia device procedures
    Disease: Version SOC Term Classification Code Term Level
    16.1 10007541 - Cardiac disorders 10003119 Arrhythmia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-001483-51 Sponsor Protocol Number: CAMN107A2101 Start Date*: 2005-07-12
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant/intolerant CML in chronic or accelerated ph...
    Medical condition: CML in chronic phase, accelerated phase or blast crisis, relapsed/refractory Ph+ ALL, systemic mastocytosis, or hypereosinophilic syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) SE (Completed) IT (Completed) DK (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-005763-28 Sponsor Protocol Number: PM-C-0225 Start Date*: 2006-10-19
    Sponsor Name:Sanofi-Aventis Groupe
    Full Title: Randomized, double-blind trial comparing the effects of a 3-month clopidogrel regimen, combined with ASA during the first month, versus ASA alone for the acute treatment of patients with TIA or mi...
    Medical condition: the acute treatment of patients with TIA or minor stroke
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008192 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) ES (Completed) AT (Completed) HU (Prematurely Ended) SK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002882-35 Sponsor Protocol Number: CA180-018 Start Date*: 2006-03-02
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Phase I study of Src/Abl tyrosine kinase inhibitor dasatinib [BMS-354825] in children and adolescents with relapsed or refractory leukemia, Protocol ITCC 005. Decision number of Paediatric Inves...
    Medical condition: Children and adolescents with CML in chronic, accelerated or blast phase who are resistant or intolerant to imatinib, or in first or subsequent relapse of Ph+ ALL after prior imatinib, or in second...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10009700 CML LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002916-34 Sponsor Protocol Number: ITCC-054/AAML1921 Start Date*: 2016-06-13
    Sponsor Name:Erasmus MC
    Full Title: A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, study ITCC-054/COG AAML1921
    Medical condition: Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009700 CML LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) IE (Completed) DE (Ongoing) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) DK (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000754-38 Sponsor Protocol Number: TMC114FD2HTX3001 Start Date*: 2015-08-19
    Sponsor Name:Janssen Sciences Ireland UC
    Full Title: A Phase 3, randomized, active-controlled, double-blind study to evaluate efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once daily fixed dose combinatio...
    Medical condition: Human Immunodeficiency Virus Type 1
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) GB (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002604-12 Sponsor Protocol Number: PSY-NIL-0010 Start Date*: 2022-02-09
    Sponsor Name:Medical University of Vienna
    Full Title: Unraveling the aesthetic mind in anhedonia, insights from pharmacological imaging of the human brain: A single-blind, randomized, placebo-controlled cross-over study
    Medical condition: Depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-001294-99 Sponsor Protocol Number: CA180-034 Start Date*: 2005-07-18
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Ph...
    Medical condition: Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia who are resistant or intolerant to Imatinib Mesylate
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) GB (Completed) HU (Completed) DK (Completed) IE (Completed) CZ (Completed) FI (Completed) IT (Completed) EE (Completed) ES (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002154-39 Sponsor Protocol Number: VINFORCE007 Start Date*: 2014-10-23
    Sponsor Name:Vinforce - Institut für Osteoporoseforschung [...]
    1. Vinforce - Institut für Osteoporoseforschung
    2. Vinforce - Institut für Osteoporoseforschung
    Full Title: Teriparatide for fracture repair in humans: A prospective, randomized, double-blind placebo-controlled pilot study in female and male patients with proximal humerus fracture The TERAFRAP Study
    Medical condition: Osteoporotic humerus fracture - accelerated fracture repair
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004859 10031288 Osteoporosis with fracture LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 15:52:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA